Revvity
Logotype for Revvity Inc

Revvity (RVTY) investor relations material

Revvity Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Revvity Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Long-range plan and 2027 outlook

  • Long-range plan reiterated: market growth assumption of 4%-6%, with core growth 200 bps above market, or 6%-8%; segment mix shifted modestly toward life sciences software and reproductive health, with immunodiagnostics slightly lower.

  • Plan excludes potential AI upside and any impact from capital deployment; 2027 assumptions expected to be further refined over the next 8-10 weeks, with specifics targeted for the 4Q call.

AI, software and research platforms

  • 2026 is expected to bring the largest number of software NPIs to date, including BioDesign, Signals AI, LabGistics and Xynthetica; AI-native development has shortened software release cycles from 18-36 months to months.

  • LabGistics is an AI-native workflow on the Signals platform, designed to bring drug discovery and development workflows together and support LLMs and AI agents; features are being launched in stages.

  • Signals is used by more than 1 million users and 46 of the top 50 pharma/biotech customers; SaaS is 30%-35% of the business and expected to double over the next few years to 60%-70%.

  • APV and net retention rate continue to grow double digits; annual trends are key indicators as organic revenue fluctuates with order renewals.

  • Pharma/biotech orders include larger instrument purchases, while public institutions building datasets and companies developing LLMs and outsourcing work to CROs are emerging customer groups.

Reagents, instruments and biopharma demand

  • Reagents remained resilient through the downturn; instrument orders are outpacing revenue, with reagent demand expected to benefit as installed instruments are tested and validated.

  • Reagent differentiation includes 24-hour delivery for 95% of orders, research engagement and quality; validated research-reagent programs can remain in place for multiple years, including emerging GLP-1 work.

  • Cellular analysis has a particularly strong backlog; pharma/biotech recovery and AI-driven validation needs are supporting demand, with reagent pull-through typically starting 2-3 quarters after instrument installation.

  • Instrument demand broadened across cellular analysis and other platforms; in vivo imaging interest is improving, while sample preparation remained soft.

  • Biopharma growth shifted from discussions to orders, led by pharma and visible first in capital spending; early-stage biotech showed initial signs of recovery but remained a small portfolio segment.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Revvity earnings date

Logotype for Revvity Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026
Revvity
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Revvity earnings date

Logotype for Revvity Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Revvity Inc., formerly known as PerkinElmer Inc., is an American life sciences and diagnostics company. It offers a wide range of health science solutions, technologies, expertise, and services, aiming to cover the complete workflow from discovery to development, and diagnosis to cure. The company primarily serves the pharmaceutical and biotechnology industries, with a special focus on cell therapy and gene therapy developments. Revvity operates in two main segments: diagnostics, and life sciences research and laboratory services markets. By providing products, services, and solutions globally, Revvity supports the diagnostics, life sciences, and applied services markets. The company is committed to driving innovation in healthcare, emphasizing the development of technologies and solutions across disease pathways. Revvity Inc. is headquartered in Waltham, Massachusetts, and its shares are listed on the NYSE.